PluriSelect
Private Company
Total funding raised: $2.5M
Overview
PluriSelect is a private, established player in the cell separation technology space, serving as an enabler for advanced research and therapeutic development. Its core business revolves around a platform technology designed to isolate specific cell types with high purity and viability, a critical need in cell therapy manufacturing and diagnostic assay development. While likely generating early revenue from research tools, its long-term value is tied to the adoption of its technologies in clinical-scale cell therapy production. The company faces competition from established instrument and reagent vendors but occupies a niche focused on specific separation methodologies.
Technology Platform
Proprietary cell separation and isolation technologies for selecting specific cell populations with high purity and viability, serving research and clinical applications.
Funding History
1Opportunities
Risk Factors
Competitive Landscape
PluriSelect competes in a crowded market dominated by global leaders like Miltenyi Biotec, BD Biosciences, and Thermo Fisher Scientific. Its success depends on demonstrating superior performance, cost-effectiveness, or ease of use for specific, high-value applications to carve out a defensible niche.